22nd January 2021 01:00 PM - 04:00 PM (GMT+01:00) Europe/London
We are going virtual!
View event programme
The British Institute of Radiology may take photos at events. These images will be used by the BIR to share news about the event and to publicise upcoming events. Images may be used in press releases, printed publicity and published on the website and social media. They will be stored securely, and will be deleted after they are no longer needed for publicity purposes.
Please note, by registering for a BIR event you are giving consent for your photo to be used by the BIR for marketing and publicity purposes. If you would prefer not to be photographed, please email the BIR events team email@example.com or speak to a member of staff on the day.
Advanced Accelerator Applications, S.A. (AAA), a Novartis company, is an innovative medicines company developing targeted radioligand therapies and precision imaging radioligands for oncology. We are committed to transforming patients’ lives by leading innovation in nuclear medicine. AAA currently has over 1,000 employees working across 31 sites in 12 countries (Canada, France, Germany, Israel, Italy, the Netherlands, Poland, Portugal, Spain, Switzerland, the UK and the US). The company also has global manufacturing capabilities with 19 facilities in eight countries, and six research & development sites. For more information, please visit: https://www.adacap.com/.
Bayer’s Radiology business is well placed to be the partner of choice in helping NHS trusts to address the many challenges faced today including the increasing need for governance to demonstrate best practice and improving patient care within increasing financial constraints. With market-leading contrast media and power injector systems, Bayer is able to offer innovative patient care and with the addition of its informatics platform, it can support radiology departments in driving protocol standardisation and easily accessible audit data that enable departments to meet further challenges faced around contrast and radiation dose management. 0118 2063999 www.radiology.bayer.co.uk
Blue Earth Diagnostics is a leading molecular imaging diagnostics company focused on the development and commercialization of novel PET imaging agents to inform clinical management and guide care for cancer patients in areas of unmet medical need. The company’s first approved and commercially available product is Axumin® (fluciclovine F 18). Blue Earth Diagnostics is a subsidiary of Bracco Imaging S.p.A..
GE Healthcare is a leading provider of medical imaging, monitoring, and life science technologies. GE Healthcare enables precision health in diagnostics, therapeutics and monitoring through intelligent devices, data analytics, applications and services to help providers, researchers and life sciences companies in their mission to improve outcomes for patients around the world.
MIM Software provides solutions in Radiology, Nuclear Medicine, and Radiation Oncology. MIM’s products emphasize the importance of quantitation, collaboration, and data management to provide physicians with the necessary information needed to generate confident clinical guidance and to inform effective treatments. MIM SurePlan™ products provide timesaving tools for organ and tumor segmentation, deformable registration, and voxel-based dosimetry. SurePlan offers reporting solutions that provide more information about the treatment course. https://go.mimsoftware.com/eu/personalized-dosimetry
OncoBeta® GmbH with its headquarters located at the Garching Technology and Founders Center GATE near Munich, is a privately held medical device and radiochemical company specialized in the development and commercialization of state-of-the-art, innovative therapies utilizing epidermal radioisotope applications. Since its foundation, OncoBeta® GmbH has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting non-melanoma skin cancers. Since then, OncoBeta® GmbH has successfully perfected the customized application and device management system in conformity with all health, safety, and environmental protection regulatory standards. Since 2019 OncoBeta® GmbH produces tungsten (wolfram)-188/rhenium-188 (188W/188Re) Generators for commercial use. Find out more about the Rhenium-SCT® at www.oncobeta.com Follow us on social media: LinkedIn: https://www.linkedin.com/company/oncobeta-gmbh/ Facebook: https://www.facebook.com/OncoBeta/
Enabling better health and better care at lower cost Philips is a leading health technology company focused on improving people`s lives across the health continuum - from healthy living and prevention, to diagnosis, treatment and home care. Applying advanced technologies and deep clinical and consumer insights, Philips delivers integrated solutions that improve people`s health and enable better outcomes. Partnering with its customers, Philips seeks to transform how healthcare is delivered and experienced. The company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. www.philips.co.uk/healthcare
At Siemens Healthineers, our purpose is to enable healthcare providers to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, and improving patient experience, all enabled by digitalising healthcare. An estimated 5 million patients globally everyday benefit from our innovative technologies and services in the areas of diagnostic and therapeutic imaging, laboratory diagnostics and molecular medicine, as well as digital health and enterprise services. We are a leading medical technology company with over 170 years of experience and 18,000 patents globally. With more than 48,000 dedicated colleagues in 75 countries, we will continue to innovate and shape the future of healthcare. For more information and latest product line, please visit https://www.siemens-healthineers.com/en-uk/